Live Breaking News & Updates on Pharma stocks

Stay informed with the latest breaking news from Pharma stocks on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Pharma stocks and stay connected to the pulse of your community

Choice Broking's Sumeet Bagadia picks Torrent Pharma as top Christmas pick; here's why

Sumeet Bagadia of Choice Broking has chosen Torrent Pharma as his ‘Christmas 2023 Pick’. Bagadia has recommended a ‘Buy’ on the pharma stock at ₹2,185 and up to ₹2,090 for a target price of ₹2,420 to ₹2,490.

India , Brazil , Motilal-oswal-financial-services , Goldman-sachs , Torrent-pharmaceuticals , Exponential-moving-average , Relative-strength-index , Choice-broking , View-full-image , Nifty-pharma , Compounded-annual-growth-rate

Pharma stocks rally up to 8% to 52-week highs amid rise in fresh Covid cases

The pharma industry is one of the few defensive industries and investor interest in it is also rising, as concerns about COVID-19 gain momentum, said Aamar Deo Singh, Senior Vice President, Research, Angel One.

India , Glenmark-pharma , Glaxosmithkline-pharma , Trastuzumab-deruxtecan , Astrazeneca-pharma , Natco-pharma , Piramal-pharma , Aurobindo-pharma , Aamar-deo-singh , Pfizer , Nifty-pharma-index , Nifty-pharma

27 Nifty 50 stocks recorded new all-time highs this year; will the rally continue in 2024?

Nifty 50 is set to end 2023 with double-digit gain, marking eighth consecutive year of positive returns. 27 constituents of the index achieved new all-time highs this year.

India , Bharti-airtel , Bajaj-finserv , Vinod-nair , Larsen-toubro , Axis-bank , Bajaj-group , Life-insurance-company , Infosys , Grasim-industries , Eicher-motors , Major-tata-group

Pharma stocks to buy: After long phase of consolidation: 4 Indian pharma stocks with upside potential of up to 41%

Between 2005 to 2015, the pharma sector was one of the best performing sectors with stocks creating big wealth for the shareholders. Then came a spate of US FDA inspections and observation and a number of companies witnessed a sharp decline in performance. Over the next few years, stocks underperformed as companies went into introspection and course correction. Some of them have been able to make a comeback both in terms of operations and product portfolio. While there are some risks present in the system but given the fact they have come into under owned category, any positive news may have higher positive impact.

Google , Market-research , Unlimited-access , Economic-times , Saver-sale , Membershipclaim-offer , Prime-story , Debit-cards , Includes-docubay , Economic-times-stories , Industry-trends

Dr Reddy's Laboratories shed around 7% as USFDA issues 3 observations for firm

Shares of Dr Reddy's Laboratories (DRL) shed almost 7 percent in trade on Monday after the US Food and Drug Administration (USFDA) issued three observations for the company's Telangana plant.

India , Reddy-bachupally , Board-of-directors-the-company , Stock-options , Employees-stock-option-scheme , Option-scheme , Dr-reddys-laboratories , Dr-reddys-laboratories-stock , Dr-reddys-laboratories-share , Dr-reddys-laboratories-share-price , Dr-reddys-laboratories-observations , Usfda

dr reddy's labs share price: Dr Reddy's Labs shares plunge 7%. Here's why

Dr Reddy's shares have slightly underperformed the Nifty Pharma index, giving returns of nearly 22% over the last 12 months versus 25% given by the latter. However, stock's returns in 2023 are a percentage point better than the Nifty Pharma Index. Meanwhile, broader Nifty50 has given over 13% and 15% returns in the last 12 months and year-to-date, respectively.

United-states , Hyderabad , Andhra-pradesh , India , America , Etmarkets-whatsapp , National-list-of-essential-medicines-impact , Us-food-drug-administration , Drug-administration , Nifty-pharma , North-america , National-list

Orchid Pharma: Investec initiates coverage with 'buy', sees 23% upside – 5 key reasons

Despite an over 86 percent gain in the stock in 2023 YTD, domestic brokerage house Investec sees pharma firm Orchid Pharma (ORCD) rising another 23 percent in the next 12 months. The brokerage has initiated coverage on the stock with a ‘buy’ call and a target price of ₹800.

India , Supriya-aarti , Business-expansion , Dhanuka-group , Contract-development , Manufacturing-organization , Production-linked-incentive , Annual-growth-rate , New-chemical-entity , India-branded , Branded-india , Driven-backward-integration

Saurabh Mukherjea picks two new smallcap stocks, exits pharma company

PDS, which acts as a link between retailers & brands in the West and small garment manufacturers in the Far East, has seen its share prices grow around 65% so far in the calendar year.

India , Cera-sanitaryware , Saurabh-mukherjea , Godrej-properties , Far-east , Little-champs-portfolio , Garware-tech , Little-champs , Gmm-pfaudler , Saurabh-mukherjea-stocks , Smallcap-stocks , Pharma-stocks

sanjiv bhasin portfolio: Sanjiv Bhasin on why pharma is better than IT to play a weak rupee & his dark horse pick

“Pharma sector can be a very good proxy to a weak rupee. Rather than IT, be in pharma to play a weak rupee. That has been a splendid outperforming sector. Cipla, Sun Pharma, Aurobindo are just coming of age and I still continue to think Lupin can be a huge outperformer.”

Lucknow , Uttar-pradesh , India , Mumbai , Maharashtra , Sanjiv-bhasin , Sun-pharma , Mamaearth-honasa , Indian-school-of-business , Godrej , Devyani-international , Cipla

pharma stocks: New tailwinds emerge! 5 midcap pharma stocks with upside potential of up to 37%

If one looks at corporate announcements, a large number of small and mid-caps pharma companies are announcing one or the other thing either about US FDA or European authorities giving approval or inspection. While the large players had moved to international markets a long time back, a number of small companies that had domestic focussed business are also moving into the developed global markets. Will this lead to re-rating?

Supriya-lifescience , Stocks-to-buy , Stock-ideas , Pharma-stocks-to-buy , Pharma-stocks , Midcaps , Indoco-remedies , Aarti-drugs ,